Pituitary Tumors-Therapeutics

OR09-1

A Phase 2 Study of Antisense Oligonucleotide Therapy Directed at the GH Receptor Demonstrates Lowering of Serum IGF-I in Patients with Acromegaly
Peter James Trainer, John Newell-Price, John Ayuk, Simon J B Aylwin, Aled Rees, William Drake, Philippe Chanson, Thierry Brue, Susan M. Webb, Carmen Fajardo, Javier Aller, Ann I McCormack, David J Torpy, George Tachas, Lynne Atley and Martin Bidlingmaier

OR09-2

Evaluation of the Effects of LCI699 (Osilodrostat) on Cytochrome P450 Enzymes in Healthy Volunteers: Low Drug-Drug Interaction Potential
Lillian Ting, Anadya Prakash Tripathi, Christelle Darstein, Tracy White and Nicholas Sauter

OR09-3

Determinants of Oral Octreotide Capsules Efficacy in Acromegaly
Shlomo Melmed, Nienke R. Biermasz, Peter J. Trainer, Gary Patou and Asi Haviv

OR09-4

Treatment with High Doses of Pegvisomant in 56 Patients with Acromegaly: Experience from Acrostudy
Aart J. van der Lely, Peter J. Jonsson, Patrick Wilton, Jose Francisco Cara and Ezio Ghigo

OR09-5

Pregnancy Outcomes in Women with Growth Hormone Deficiency Are Not Related to Growth Hormone Treatment during Pregnancy - a Long-Term Observational Study
Greisa Vila, Ann-Charlotte Akerblad, Anders F. Mattsson, Michaela Riedl, Susan M. Webb, Vaclav Hana, Eigil H Nielsen, Beverly M.K. Biller and Anton Luger

OR09-6

Incidence of New Neoplasia in Growth Hormone Treated Adult Patients with Pituitary Deficiency Following Childhood or Adulthood Malignancy
Katarzyna Kryzanowska-Mittermayer, Anton Luger, Dominique Maiter, Ulla Feldt-Rasmussen, Anders F. Mattsson, Ann-Charlotte Akerblad, Nina Camacho-Hubner and Roger Abs